ERBB2 and gastroesophageal junction adenocarcinoma: In the DESTINY-Gastric01 trial, trastuzumab-deruxtecan was compared to chemotherapy in patients with HER2-positive advanced GC and GEJ adenocarcinoma from Japan and South Korea.100 Overall survival was longer with trastuzumab-deruxtecan than with chemotherapy (12.5 versus 8.4 months), leading to the approval of the drug.